Flagship Financial Year for Cannabis Science (CBIS:OTC.QB) Arrives Amid New Medical Marijuana Legislation

Business & Professional Services

Share Tweet

Flagship Financial Year for Cannabis Science (CBIS:OTC.QB) Arrives Amid New Medical Marijuana Legislation

BOCA RATON, FL / ACCESSWIRE / July 24, 2014 / In the fast growing small cap market of medical marijuana companies we believe Cannabis Science stands out among its peers such as American Green (ERBB: OTC.PK), Medical Marijuana, Inc (MJNA:OTC.PK), Hemp, Inc (HEMP:OTC.PK) and Abattis Bioceuticals Corp (ATTBF:OTC.QX) 

Cannabis Science (CBIS:OTC.QB) , a one-of-a-kind biotech dedicated to the formulation of alternative cannabinoid therapies, continued its flagship year just as new legislation trickled in from New York legalizing the use of medical marijuana. The Compassionate Care Act, which is expected to pass through the legislature, would make New York the 23rd state to legalize the drug, potentially allowing marijuana to be prescribed to severely ill patients with medical ailments ranging from epilepsy to AIDS. The bill is just one in a long line of new legislation shifting cultural perspectives on medicinal cannabinoid treatment. Colorado famously instituted the public sale of marijuana in 2014 after a vote to legalize the drug in 2012, and the state has witnessed the cannabis market continue to boom throughout the year.

CBIS, currently trading at .08 cents a share with an average volume of about 8 million, is an under-the-radar stock with the potential to benefit from the recent news out of New York, as well as the social and economic trends signifying more widespread acceptance of the drug. The experienced personnel at Cannabis Science have laid the groundwork for long term success in the budding cannabis industry with a business plan founded on research, partnerships, and wise use of investment resources.

In addition to several recent announcements of clinical trials and other research surrounding their in-house, proprietary formulations of cannabinoid treatments, the company made waves with its financial postings. In the last fiscal year ending March 31st, CBIS has tripled its Total Assets and lowered its net losses by nearly two thirds, all while raising sufficient capital with which to invest in its pre-clinical drug development. One of their primary assets, CS-TATI-1, is an experimental, cannabinoid-based drug with antiviral properties that could revolutionize the treatment of Epidemic Kaposi Sarcoma, a form of cancer affecting people with certain strains of HIV.

On the partnership front, Cannabis Science recently signed a distribution agreement with MDS, which is owned by Medbox Inc., that will garner the company half the gross profits on MDS equipment sold in markets across nearly every continent on earth. Additionally, a unique partnership with Dutch cannabis company Mediwiet will allow Cannabis Science to conduct one of the world’s largest observational studies on medicinal cannabis-based medicine. Researchers predict that the observational study will provide raw data regarding the medical effectiveness of medicinal cannabis on a wide array of illnesses, and follow-up studies are expected to commence in the United States in the coming weeks.

Just as medical marijuana begins to find its stride in the U.S., Cannabis Science has aligned several resources and partnerships that it holds worldwide to capitalize on a specialized, but wide-ranging sector of the burgeoning American market. Marked by both an expertise in the science behind cannabinoid therapies and a keen eye for financial and economic trends in the industry, CBIS is a well-rounded biotech stock that boasts definitive assets and agendas. With landmark legislation opening up new, untapped markets seemingly every week, CBIS should prove to be an attractive option for investors looking for a robust entry-level stock in this fast-growing industry.

Always read full disclaimer/disclosure: http://tomorrowsbluechips.com/disclaimer/

TomorrowsBlueChips.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. All information that we provide is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Furthermore, investing in such securities involves substantial risk of loss and investors should seek advice from financial professionals before investing.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.


Source: TomorrowsBlueChips